ReviewInternational journal of general medicine2022
A Review on the Diagnosis and Treatment of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits.
Review in International journal of general medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 8 citations in OpenAlex.
- Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients.Frontiers in immunology · 2026Trial
- Proliferative glomerulonephritis with monoclonal IgG3 deposits: A case series.Journal of translational autoimmunity · 2026Article
- Article
- Article
- Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria.Frontiers in medicine · 2026Article
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposits masquerading as renal-specific thrombotic microangiopathy.BMJ case reports · 2025Article
- Concurrent presentation of proliferative glomerulonephritis with monoclonal immunoglobulin deposits and light chain proximal tubulopathy: a case report and review of the literature.Frontiers in medicine · 2025Article
- Proliferative glomerulonephritis with monoclonal immunoglobulin deposition coexisting with ANCA-associated glomerulonephritis: a case report.Frontiers in immunology · 2025Article
- IgM kappa proliferative glomerulonephritis with monoclonal immunoglobulin deposition complicated with nocardiosis dermatitis: a case report and review of literature.Frontiers in medicine · 2024Article
- Unraveling monoclonal gammopathy of renal significance: a mini review on kidney complications and clinical insights.Frontiers in nephrology · 2024Review
- Contemporary Monoclonal Antibody Utilization in Glomerular Diseases.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Review
- Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: An Immunologic Crossroads.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a new entity of monoclonal gammopathy of renal significance (MGRS) due to monoclonal immunoglobulin (mIg) deposits in the glomerulus leading to kidney injury. Patients with PGNMID typically present with proteinuria, haematuria, and abnormal renal function. Only ~30% of patients have a detectable clone in the blood, urine or bone marrow. Histologically, the membranoproliferative glomerulonephritis (MPGN) pattern of injury is the most common, with approximately 50% of patients demonstrating IgG3κ monoclonal deposition in the glomerulus. Approximately 20% of PGNMID patients progress to end-stage kidney disease (ESΚD), and recurrence with renal allograft is frequent. Treatment of PGNMID relies on targeting identifiable B-cell or plasma cell clones. Due to the relatively short history of research on this disease and incomplete understanding, it is easy to misdiagnose and miss diagnosis, and there are also objections on how to treat it. Therefore, we review the development of PGNMID understanding in the past 20 years and discuss this new entity from a holistic and progressive perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.